Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $34.6 million.

  • Ironwood Pharmaceuticals' Accumulated Expenses rose 314.01% to $34.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.6 million, marking a year-over-year increase of 314.01%. This contributed to the annual value of $26.8 million for FY2024, which is 3932.98% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Accumulated Expenses stood at $34.6 million for Q3 2025, which was up 314.01% from $24.0 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Accumulated Expenses ranged from a high of $79.6 million in Q2 2023 and a low of $13.4 million during Q2 2022
  • For the 5-year period, Ironwood Pharmaceuticals' Accumulated Expenses averaged around $29.7 million, with its median value being $24.0 million (2025).
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Accumulated Expenses soared by 49281.19% in 2023, and later plummeted by 5928.13% in 2024.
  • Ironwood Pharmaceuticals' Accumulated Expenses (Quarter) stood at $23.6 million in 2021, then decreased by 29.14% to $16.7 million in 2022, then soared by 164.99% to $44.3 million in 2023, then tumbled by 39.33% to $26.8 million in 2024, then grew by 28.94% to $34.6 million in 2025.
  • Its Accumulated Expenses stands at $34.6 million for Q3 2025, versus $24.0 million for Q2 2025 and $33.4 million for Q1 2025.